Generic Name: Crixivan
What is Crixivan?
Greater levels of resistance were associated with the expression of multiple amino acid substitutions. Cross-resistance to ritonavir has been noted. In vitro studies show that the oxidative metabolites are generated as a result of metabolism by the cytochrome P450 3A4 enzyme. The elimination half-life is about 2 hours. Affected cytochrome P450 isoenzymes and drug transporters: CYP3A4, CYP2D6, P-gp, UGT1A1Indinavir is a substrate of CYP3A4 and P-glycoprotein P-gpa significant inhibitor of CYP3A4, and may be a weak inhibitor of CYP2D6.
Studies have also found indinavir to be an inhibitor of uridine diphosphoglucuronosyltransferase UGT1A1. Following administration, indinavir is rapidly absorbed in the fasting state. Peak concentrations occur in 0. Your email has been sent.
Research studies with animals found harmful effects on unborn babies.
Indinavir inhibits CYP3A4 metabolism. Because fluvastatin does not rely exclusively on CYP3A4 for its metabolism, indinavir may not interact to the same extent as expected with other HMG-CoAA reductase inhibitors. Food: Administration with food high in calories, fat, and protein results in a decrease in the AUC and Cmax of indinavir.
The pharmacokinetic parameters of anti-retroviral medications anti-retroviral non-nucleoside reverse transcriptase inhibitors NNRTIsanti-retroviral nucleoside reverse transcriptase inhibitors NRTIsanti-retroviral nucleotide reverse transcriptase inhibitors, and anti-retroviral protease inhibitors metabolized through the CYP isoenzyme system are slightly altered by smoked and oral marijuana.
Despite this interaction, marijuana is not expected to adversely affect anti-retroviral efficacy. However, the incidence of marijuana associated adverse effects may change following coadministration with anti-retroviral drugs. Many anti-retrovirals are inhibitors of CYP3A4, an isoenzyme partially responsible for the metabolism of marijuana's most psychoactive compound, delta-9-tetrahydrocannabinol Delta-9-THC.
When given concurrently with anti-retrovirals, the amount of Delta-9-THC converted to the active metabolite 11-hydroxy-delta-9-tetrahydrocannabinol 11-OH-THC may be reduced. These changes in Delta-9-THC and 11-OH-THC plasma concentrations may result in an altered marijuana adverse event profile. Fosphenytoin: Hydantoins like phenytoin, ethotoin, fosphenytoin may increase the metabolism of indinavir and lead to decreased efficacy. Galantamine: Indinavir inhibits cytochrome P450 3A4.
Although specific interactions have not been studied, indinavir may interfere with the metabolism of CYP3A4 substrates, such as galantamine, and caution is warranted with coadministration. Gefitinib: Monitor for an increased incidence of gefitinib-related adverse effects if gefitinib and indinavir are used concomitantly.
Grapefruit juice: Concurrent grapefruit juice may decrease indinavir levels by 26 percent. Individuals should not drastically alter their intake of grapefruit juice or should avoid concurrent use unless advised differently by their healthcare professional.
How should I take Crixivan?
Antiretroviral drugs chartA one-page reference guide to the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions. An introduction to key issues about HIV treatment and living with HIV, presented as a series of illustrated leaflets.
Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care. A one-page reference guide to the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions.
What should I avoid while taking Crixivan?
Treatmentrelated increases over controls in the incidence of supernumerary ribs at exposures at or below those in humans and of cervical ribs at exposures comparable to or slightly greater than those in humans were seen in rats. A similar exacerbation did not occur in neonates after in utero exposure to indinavir during the third trimester of pregnancy. It is unknown whether CRIXIVAN administered to the mother in the perinatal period will exacerbate physiologic hyperbilirubinemia in neonates.
There are no adequate and well-controlled studies in pregnant patients. CRIXIVAN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. A CRIXIVAN dose of 800 mg every 8 hours with zidovudine 200 mg every 8 hours and lamivudine 150 mg twice a day has been studied in 16 HIV-infected pregnant patients at 14 to 28 weeks of gestation at enrollment study PACTG 358.
Crixivan side effects
Ketoconazole, a strong CYP3A4 inhibitor increases the systemic exposure of ospemifene by 1. Oxybutynin: Oxybutynin is metabolized by CYP3A4. Caution should be used when oxybutynin is given in combination with inhibitors of CYP3A4, such as protease inhibitors. Monitor for adverse effects if these drugs are administered together. Oxycodone: Coadministration of indinavir, a potent CYP3A4 inhibitor, and oxycodone, a CYP3A4 substrate, may increase oxycodone plasma concentrations and increase or prolong related toxicities including potentially fatal respiratory depression.
Common Crixivan ide effects may include:
The concomitant use of these agents together is contraindicated during the initial and dose titration phase of venetoclax.
Overdose If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911.
Substantially increased tadalafil plasma concentrations may result in increased adverse events including hypotension, syncope, visual changes, and prolonged erection.
A decrease in the flurazepam dose may be needed.
Concomitant use of ritonavir and female sex both predicted increased availability. They also encouraged drug concentration monitoring. However, close attention has to be paid to adverse effects for example nephrolithiasis when exposing patients to regimens with higher dosages than have previously been recommended.
Where can I get more information?
When the CYP3A4 inhibitor is withdrawn, the cariprazine dosage may need to be increased.
Alosetron: Concomitant use of alosetron with indinavir may result in increased serum concentrations of alosetron and increase the risk for adverse reactions.